ARS Pharmaceuticals, Inc. Shareholders' Equity
ARS Pharmaceuticals, Inc. (SPRY) had Shareholders' Equity of $12.51 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $12.51M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $61.31M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $114.26M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $147.66M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $12.51M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $61.31M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $114.26M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $147.66M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $192.32M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $228.97M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $256.80M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $200.98M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $215.24M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $223.87M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $230.76M 10-K · filed 2026-03-09 | |
| 2023-09-30 | $237.28M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $248.55M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $261.15M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $272.89M 10-K · filed 2025-03-20 | |
| 2022-09-30 | -$50.16M 10-Q · filed 2023-11-09 | $267.07M 10-Q · filed 2022-11-02 |
| 2022-06-30 | -$44.03M 10-Q · filed 2023-11-09 | $278.79M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$38.26M 10-Q · filed 2023-11-09 | $293.23M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$31.27M 10-K · filed 2024-03-21 | $313.81M 10-K · filed 2022-03-31 |
| 2021-09-30 | $332.13M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $349.65M 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $368.55M 10-Q · filed 2022-11-02 | |
| 2020-12-31 | -$14.05M 10-K · filed 2023-03-23 | $382.88M 10-Q · filed 2021-05-13 |
| 2020-09-30 | -$78.25M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$70.34M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | -$64.00M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | -$58.78M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |